Peregrine Pharmaceuticals | PPHM - Current Liabilities


Peregrine Pharmaceuticals reported $74.16M in Current Liabilities for its fiscal quarter ending in October of 2024.



Current Liabilities Change Date
Agenus USD 323.49M 36.36M Dec/2025
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Celldex Therapeutics USD 51.47M 481K Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Intrexon USD 23.02M 38K Jun/2024
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
MannKind USD 134.56M 36.47M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
Repligen USD 126.21M 9.62M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Xencor USD 73.46M 22.45M Mar/2026